A recent study, led by Prof. Brian K. Coombes from the Department of Biochemistry and Biomedical Sciences at the McMaster University in Hamilton, Ontario (Canada), has found that AIEC colonization along with acute infectious gastroenteritis worsened clinical outcome and increased mortality in mice, and also that the infectious diarrhoea caused by microbes promoted growth of AIEC and heightened the inflammatory state in the gut.

The observed success of the low-FODMAP diet in reducing gastrointestinal (GI) symptoms in IBS made a group of researchers ask whether the diet could also address functional GI symptoms in those with inflammatory bowel diseases (IBDs) such as Crohn's disease. This idea was explored in a recent study from the group at Monash University (Australia) that originally developed and tested the low-FODMAP diet.

Inflammatory bowel disease (IBD) is a family of intestinal disorders including Crohn’s disease (CD) and ulcerative colitis (UC) that are characterized by chronic and recurring periods of severe colonic (UC) or intestinal (CD) inflammation and extraintestinal symptoms.

Digestive disorders, from gut discomfort to inflammatory bowel diseases (IBD) and cancer, are rising in many countries. Research and clinical studies on the interaction of gut microbiota and digestive health, are providing stimulating data. However, their connection is not fully understood and gut fungi have recently been suggested to play a role as well.

Faecalibacterium prausnitzii is known for exhibiting anti-inflammatory effects in vitro and in vivo by secreted metabolites that block nuclear factor (NF)-κB activation. The low proportion of F. prausnitzii in the microbiome of Crohn’s disease patients characterizes the microbial dysbiosis associated with that condition.